2024
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
Rüschoff J, Kumar G, Badve S, Jasani B, Krause E, Rioux-Leclercq N, Rojo F, Martini M, Cheng L, Tretiakova M, Mitchell C, Anders R, Robert M, Fahy D, Pyle M, Le Q, Yu L, Glass B, Baxi V, Babadjanova Z, Pratt J, Brutus S, Karasarides M, Hartmann A. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments. Virchows Archiv 2024, 484: 597-608. PMID: 38570364, DOI: 10.1007/s00428-024-03795-8.Peer-Reviewed Original ResearchConceptsPD-L1 expressionImmune checkpoint inhibitorsPD-L1Tumor cellsAssess programmed death ligand 1Assessment of PD-L1 expressionScoring of PD-L1 expressionInternational multi-institutional studyPD-L1 expression analysisFood and Drug Administration-approvedPD-L1 stainingDeath-ligand 1Drug Administration-approvedMulti-institutional studyCheckpoint inhibitorsUrothelial carcinomaPathological assessmentBiomarker expressionInterobserver variabilityLigand 1Cancer treatmentExpert pathologistsClinical settingMultinational studyPositive rate
2023
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsa I, Kumar G, Karasarides M, Anders R. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology 2023, 36: 100154. PMID: 36925069, DOI: 10.1016/j.modpat.2023.100154.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 expressionCheckpoint inhibitor therapyPD-L1Tumor cellsImmune cellsIntraclass correlation coefficientInhibitor therapyInterpretation of PD-L1 expressionPD-L1 combined positive scoreInterobserver variabilityBiopsy samplesEvaluate PD-L1 expressionImmune checkpoint inhibitor therapyInterpathologist agreementProgrammed death-ligand 1PD-L1 immunohistochemistryDeath-ligand 1Variable intensity of stainingIntensity of stainingPositive scoresRetrospective histologic reviewPretreatment biopsiesTumor stainingHistologic review
2021
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma
Gao Y, Wang M, Guo X, Hu J, Chen TM, Finn S, Lacy J, Kunstman JW, H. C, Bellin MD, Robert ME, Desir GV, Gorelick FS. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. PLOS ONE 2021, 16: e0250539. PMID: 34587190, PMCID: PMC8480607, DOI: 10.1371/journal.pone.0250539.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Pancreatic DuctalCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMonoamine OxidaseNeoplasm GradingPancreatic NeoplasmsPrognosisProspective StudiesRetrospective StudiesSurvival AnalysisUp-RegulationYoung AdultConceptsPlasma renalase levelsBorderline resectable PDACRenalase levelsPDAC precursor lesionsOverall survivalPDAC tissuesTumor characteristicsResectable PDACChronic pancreatitisPrecursor lesionsNormal pancreasPancreatic ductal adenocarcinoma growthAdvanced tumor characteristicsVaried clinical stagesWorse tumor characteristicsNode-positive diseasePancreatic ductal adenocarcinomaNormal pancreatic headSpindle-shaped cellsPlasma renalaseRenalase expressionUnderwent resectionAbdominal traumaPancreatic headPositive disease
2019
Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor
Hwang MJ, Bryant KG, Seo JH, Liu Q, Humphrey PA, Melnick MAC, Altieri DC, Robert ME. Syntaphilin Is a Novel Biphasic Biomarker of Aggressive Prostate Cancer and a Metastasis Predictor. American Journal Of Pathology 2019, 189: 1180-1189. PMID: 31079810, PMCID: PMC6560381, DOI: 10.1016/j.ajpath.2019.02.009.Peer-Reviewed Original ResearchConceptsProstate cancerTumor bulkInvasive frontHigh Gleason grade prostate cancerLocalized prostate cancerGrade prostate cancerAggressive prostate cancerCell proliferationKi-67 labelingTumor cell proliferationMetastasis predictorMetastatic diseaseDistant metastasisGleason gradeAccessible biomarkersProstate tumorsMetastatic potentialNovel markerCancerBiphasic patternProliferative rateHigh expressionOxidative metabolismReduced levelsTumors
2018
Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1
Schuette D, Moore LM, Robert ME, Taddei TH, Ehrlich BE. Hepatocellular Carcinoma Outcome is Predicted by Expression of Neuronal Calcium Sensor 1. Cancer Epidemiology Biomarkers & Prevention 2018, 27: cebp.0167.2018. PMID: 29789326, PMCID: PMC8465775, DOI: 10.1158/1055-9965.epi-18-0167.Peer-Reviewed Original ResearchConceptsNeuronal calcium sensor-1Hepatocellular carcinomaDisease outcomePrognostic biomarkerIncidence of HCCWorse disease outcomesCancer-related deathLiver cancer cohortExpression levelsFurther functional assessmentEarly tumor detectionProspective cohortAsian patientsPatient survivalVariety of Ca2Tumor microarrayHCC patientsMetastatic cancerBreast cancerCancer cohortAggressive phenotypeNovel biomarkersFunctional assessmentPredictive valueTumor progression
2001
Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study
Montgomery E, Goldblum J, Greenson J, Haber M, Lamps L, Lauwers G, Lazenby A, Lewin D, Robert M, Washington K, Zahurak M, Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: A follow-up study based on 138 cases from a diagnostic variability study. Human Pathology 2001, 32: 379-388. PMID: 11331954, DOI: 10.1053/hupa.2001.23511.Peer-Reviewed Original ResearchConceptsHigh-grade dysplasiaLow-grade dysplasiaBarrett's esophagusInvasive carcinomaMajority diagnosisCases of HGDCases of LGDCases of BEEndoscopic biopsy specimensKaplan-Meier statisticsInitial biopsyEndoscopic surveillanceUlcerated areaGastrointestinal pathologyBiopsy specimenPredictive markerBiopsy diagnosisBiopsy specimensIntramucosal carcinomaPrecursor lesionsIND casesPowerful prognosticatorCarcinomaMorphologic evaluationUlcerated cases